曲美他嗪在缺血性心肌病心力衰竭治疗中的作用  

The role of trimetazidine in the treatment of heart failure in ischemic cardiomyopathy

作　　者：于长禹 屈春红[1] YU Chang-yu;QU Chun-hong(Jinzhou Central Hospital,Jinzhou 121000,China)

机构地区：[1]锦州市中心医院,121000

出　　处：《中国实用医药》2023年第6期91-93,共3页China Practical Medicine

摘　　要：目的 研究分析曲美他嗪对于缺血性心肌病心力衰竭的治疗效果。方法 115例缺血性心肌病心力衰竭患者,按照随机分配法分为实验组(57例)和参照组(58例)。参照组患者实施常规的抗心力衰竭治疗,实验组患者在接受常规抗心力衰竭治疗的基础上应用曲美他嗪展开治疗。比较两组患者治疗前后左心室射血分数、心排血量、心胸比、脑钠肽水平以及治疗效果、不良反应(呕吐以及腹部不适症状)发生情况。结果 治疗后,两组患者的左心室射血分数、心排血量、心胸比、脑钠肽水平均优于治疗前,且实验组患者左心室射血分数(51.26±11.94)%、心排血量(4.79±1.24)L/min、心胸比(52.00±11.00)%、脑钠肽(716.31±117.68)pg/ml均优于参照组的(44.67±12.30)%、(3.59±1.13)L/min、(57.00±12.00)%、(859.21±136.48)pg/ml,差异均具有统计学意义(P<0.05)。实验组治疗总有效率91.23%高于参照组的70.69%,差异具有统计学意义(χ^(2)=7.838,P=0.005<0.05)。两组不良反应发生率比较,差异无统计学意义(χ^(2)=0.102,P=0.749>0.05)。结论 在缺血性心肌病心力衰竭患者的治疗中应用曲美他嗪治疗能够有效提高治疗效果,改善患者的心功能。Objective To study and analyze the effect of trimetazidine in the treatment of heart failure in ischemic cardiomyopathy.Methods A total of 115 patients with heart failure secondary to ischemic cardiomyopathy were randomly divided into the experimental group(57 patients)and the reference group(58 patients).Patients in the reference group were treated with conventional anti-heart failure therapy,and patients in the experimental group were treated with trimetazidine on the basis of conventional anti-heart failure therapy.Both groups were compared in terms of left ventricular ejection fraction,cardiac output,cardiothoracic ratio and brain natriuretic peptide level before and after treatment,as well as therapeutic effect,and the occurrence of adverse reactions(vomiting and abdominal discomfort).Results After treatment,the left ventricular ejection fraction,cardiac output,cardiothoracic ratio,and brain natriuretic peptide levels in both groups were better than those before treatment in this group;the left ventricular ejection fraction(51.26±11.94)%,cardiac output(4.79±1.24)L/min,cardiothoracic ratio(52.00±11.00)%,and brain natriuretic peptide(716.31±117.68)pg/ml in the experimental group were better than(44.67±12.30)%,(3.59±1.13)L/min,(57.00±12.00)%,and(859.21±136.48)pg/ml in the reference group;the differences were all statistically significant(P<0.05).The total effective rate of treatment in the experimental group was 91.23%,which was higher than 70.69%in the reference group,and the difference was statistically significant(χ^(2)=7.838,P=0.005<0.05).The difference was not statistically significant when comparing the incidence of adverse reactions between the two groups(χ^(2)=0.102,P=0.749>0.05).Conclusion Trimetazidine can effectively improve the therapeutic effect and improve the heart function of patients with heart failure secondary to ischemic cardiomyopathy.

关 键 词：曲美他嗪 缺血性心肌病心力衰竭 临床疗效 

分 类 号：R541.6[医药卫生—心血管疾病] R542.2[医药卫生—内科学]